Company Atossa Genetics Inc Nasdaq
Equities
US04962H1005
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-15 | Atossa Therapeutics Doses Last Patient in Phase 2 Karisma-Endoxifen Trial | MT |
05-15 | Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial | CI |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 08-11-30 |
Steven Quay
CEO | Chief Executive Officer | 73 | 08-11-30 |
Heather Rees
DFI | Director of Finance/CFO | - | 16-12-31 |
Arezoo Mirad
CTO | Chief Tech/Sci/R&D Officer | - | 12-03 |
Richard Graydon
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-24 |
Delly Behen
ADM | Chief Administrative Officer | - | 13-12-31 |
Eric van Zanten
IRC | Investor Relations Contact | - | 22-12-06 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 08-11-30 |
Director/Board Member | 66 | 14-02-28 | |
H. Remmel
BRD | Director/Board Member | 72 | 12-01-31 |
Shu-Chih Chen
FOU | Founder | 62 | 08-11-30 |
Stephen Galli
BRD | Director/Board Member | 77 | 11-06-30 |
Jonathan Finn
BRD | Director/Board Member | 50 | 11-07 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 127,077,462 | 125,684,004 ( 98.90 %) | 1,320,046 ( 1.039 %) | 98.90 % |
Stock B | 0 | 582 | 0 | 0 |
Company contact information
Atossa Therapeutics, Inc.
107 Spring Street
98104, Seattle
+206 588 0256
http://www.atossatherapeutics.comSector
1st Jan change | Capi. | |
---|---|---|
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- ATOS Stock
- Stock
- Company Atossa Genetics Inc